U.S. health advisers said GlaxoSmithKline Plc's GSK.L diabetes drug Avandia should be allowed to stay on the market in some form, easing a threat of further litigation that could have followed a ban.
The 33-member panel of outside experts convened by the U.S. Food and Drug Administration cast 20 votes for various options that would allow Avandia to stay on the market despite concerns over associated heart risks.
The agency will make the final decision in the coming months but usually follows the advice of its advisory committees.
Avandia's U.S. sales were just 1.5 percent of Glaxo's 2009 revenues, but investors feared the company could face more lawsuits if the drug was forced from the market. [ID:nN1397641 ]
The advisory panel heard two days of sharply conflicting opinions from inside and outside the FDA, and reviewed hundreds of pages of data, before coming to its decision.
The debate on Avandia's safety has raged since warnings were placed on the drug in 2007 saying some research linked the drug to a higher heart attack risk but the data was "inconclusive."
U.S.-listed shares of Britain-based Glaxo GSK.N were trading up 2 percent on the New York Stock Exchange, having closed up 0.4 percent in London ahead of the vote.
(More information on the controversy and its impact on those with diabetes can be found at www.healthkey.com.)
Experts Vote to Keep Avandia
The 33-member panel convened by the U.S. Food and Drug Administration cast 20 votes for various options that would allow the diabetes drug to stay on the market despite concerns over associated heart risks.
We've upgraded our reader commenting system. Learn more about the new features.
The Baltimore Sun encourages civil dialogue related to our stories; you must register and log-in to our site in order to participate. We reserve the right to remove any user and to delete comments that violate our Terms of Service. By commenting, you agree to these terms. Please flag inappropriate comments.